Satoru Iwasa

6.6k total citations · 2 hit papers
255 papers, 4.4k citations indexed

About

Satoru Iwasa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Satoru Iwasa has authored 255 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 156 papers in Oncology, 136 papers in Pulmonary and Respiratory Medicine and 75 papers in Surgery. Recurrent topics in Satoru Iwasa's work include Gastric Cancer Management and Outcomes (104 papers), Colorectal Cancer Treatments and Studies (71 papers) and Esophageal Cancer Research and Treatment (37 papers). Satoru Iwasa is often cited by papers focused on Gastric Cancer Management and Outcomes (104 papers), Colorectal Cancer Treatments and Studies (71 papers) and Esophageal Cancer Research and Treatment (37 papers). Satoru Iwasa collaborates with scholars based in Japan, United States and South Korea. Satoru Iwasa's co-authors include Ken Kato, Kensei Yamaguchi, Yasuhide Yamada, Yoshitaka Honma, Atsuo Takashima, Kohei Shitara, Tetsuya Hamaguchi, Kaku Saito, Yasuhiro Shimada and Masahiro Sugihara and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Satoru Iwasa

238 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer

2020 802 citations Kohei Shitara, Yung‐Jue Bang et al. profile →
Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

2017 292 citations Toshihiro Kudo, Yasuo Hamamoto et al. The Lancet Oncology profile →

Peers

Countries citing papers authored by Satoru Iwasa

Since Specialization

Citations

This map shows the geographic impact of Satoru Iwasa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Satoru Iwasa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Satoru Iwasa more than expected).

Fields of papers citing papers by Satoru Iwasa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Satoru Iwasa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Satoru Iwasa. The network helps show where Satoru Iwasa may publish in the future.

Co-authorship network of co-authors of Satoru Iwasa

This figure shows the co-authorship network connecting the top 25 collaborators of Satoru Iwasa. A scholar is included among the top collaborators of Satoru Iwasa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Satoru Iwasa. Satoru Iwasa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin 2024 ·In Vivo ·(unknown), Shun Yamamoto, Yoshitaka Honma, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Akihito Nagahara, Ken Kato	2
2	Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program 2024 ·Clinical Colorectal Cancer ·Daisuke Kotani, Atsuo Takashima, Takeshi Kato, Taroh Satoh, Toshiki Masuishi, Yoshito Komatsu, Manabu Shiozawa, (unknown), Naoki Izawa, Shinji Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, (unknown), Hiroya Taniguchi, (unknown), (unknown), Chiaki Inoue, Takayuki Yoshino	3
3	Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab 2023 ·Cancer Medicine ·(unknown), Satoru Iwasa, Kengo Nagashima, (unknown), Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku	2
4	P-23 Clinical outcomes of encorafenib, binimetinib, and cetuximab for pretreated BRAF V600E-mutant metastatic colorectal cancer in the BEACON EAP follow-up study 2023 ·Annals of Oncology ·Takeshi Kato, (unknown), Atsuo Takashima, Taroh Satoh, (unknown), Yoshito Komatsu, Manabu Shiozawa, Taito Esaki, (unknown), Satoshi Takeuchi, Hideaki Bando, Satoru Iwasa, Hiroko Hasegawa, Tomohiro Yamaguchi, (unknown), Satoshi Yamada, Takayuki Yoshino	1
5	First‐in‐human study of ONO‐4578, an antagonist of prostaglandin E₂ receptor 4, alone and with nivolumab in solid tumors 2022 ·Cancer Science ·Satoru Iwasa, Takafumi Koyama, Makoto Nishino, Shunsuke Kondo, Kazuki Sudo, Kan Yonemori, Tatsuya Yoshida, Kenji Tamura, Toshio Shimizu, Yutaka Fujiwara, Shigehisa Kitano, Akihiko Shimomura, Jun Sato, (unknown), Hiroyuki Iida, Maki Kondo, Noboru Yamamoto	13
6	Trastuzumab Deruxtecan in Anti–Human Epidermal Growth Factor Receptor 2 Treatment–Naive Patients With Human Epidermal Growth Factor Receptor 2–Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial 2022 ·Journal of Clinical Oncology ·Kensei Yamaguchi, Yung‐Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min‐Hee Ryu, Daisuke Sakai, Hyun Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Tatsu Shimoyama, Keun‐Wook Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, (unknown), Masahiro Sugihara, Kohei Shitara	76
7	Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study 2022 ·Cancer Research Communications ·Yasutoshi Kuboki, Toshio Shimizu, Kan Yonemori, Takashi Kojima, Shunsuke Kondo, (unknown), Satoru Iwasa, Kenichi Harano, Takafumi Koyama, (unknown), Xiaofei Zhou, Huifeng Niu, Tomoko Yanai, Ignacio Garcia‐Ribas, Toshihiko Doi, Noboru Yamamoto	7
8	Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer 2022 ·Cancer Medicine ·Hibiki Udagawa, Shunji Takahashi, Motohiro Hirao, Makoto Tahara, Satoru Iwasa, Yasuyoshi Sato, Takuya Hamakawa, Kohei Shitara, Hidehito Horinouchi, Keisho Chìn, Norikazu Masuda, Takuya Suzuki, (unknown), (unknown), (unknown), Kan Yonemori	9
9	Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study 2022 ·International Journal of Clinical Oncology ·Shunsuke Kondo, Satoru Iwasa, Takafumi Koyama, Tomoko Fujita, (unknown), (unknown), Noboru Yamamoto	11
10	Association of renal function with the safety and efficacy of cisplatin plus S-1 therapy and docetaxel plus cisplatin plus S-1 therapy in patients with advanced gastric cancer: an exploratory analysis of JCOG1013 2021 ·Japanese Journal of Clinical Oncology ·Shuichi Hironaka, Ryo Sadachi, Nozomu Machida, Satoru Iwasa, Yasuhide Yamada, Mitsuru Sasako, Takaki Yoshikawa, Narikazu Boku, Masanori Terashima	0
11	Long‐term efficacy and predictive correlates of response to nivolumab in Japanese patients with esophageal cancer 2020 ·Cancer Science ·Ken Kato, Yuichiro� Doki, Takashi Ura, Yasuo Hamamoto, Takashi Kojima, Takahiro Tsushima, Shuichi Hironaka, Hiroki Hara, Toshihiro Kudo, Satoru Iwasa, Kei Muro, Hirofumi Yasui, Keiko Minashi, Kensei Yamaguchi, Atsushi Ohtsu, Yuko Kitagawa	23
12	First‐in‐human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors 2020 ·Cancer Science ·Shunsuke Kondo, Toshio Shimizu, Takafumi Koyama, Jun Sato, Satoru Iwasa, Kan Yonemori, Yutaka Fujiwara, Akihiko Shimomura, Shigehisa Kitano, Kenji Tamura, Noboru Yamamoto	7
13	17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors 2020 ·Annals of Oncology ·Junichiro Sato, T. Shimizu, Yasuhiro Fujiwara, Kan Yonemori, (unknown), Atsushi Shimomura, Keita Tamura, Satoru Iwasa, Shunsuke Kondo, Kentaro Sudo, Hiroki Ikezawa, (unknown), R. Nakajima, Takuma Miura, Nobuyuki Yamamoto	1
14	First‐in‐human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors 2019 ·Cancer Science ·Takafumi Koyama, Toshio Shimizu, Satoru Iwasa, Yutaka Fujiwara, Shunsuke Kondo, Shigehisa Kitano, Kan Yonemori, Akihiko Shimomura, (unknown), Tatsuya Sasaki, Junji Furuse, Noboru Yamamoto	24
15	Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer 2019 ·International Journal of Clinical Oncology ·Ryo Otsuka, Satoru Iwasa, Takako Yanai, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Hironobu Hashimoto, (unknown), Yoshinori Makino, Narikazu Boku, Masakazu Yamaguchi	5
16	Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study 2019 ·The Lancet Oncology ·Kohei Shitara, Hiroji Iwata, Shunji Takahashi, Kenji Tamura, Haeseong Park, Shanu Modi, Junji Tsurutani, Shigenori Kadowaki, Kensei Yamaguchi, Satoru Iwasa, Kaku Saito, Yoshihiko Fujisaki, Masahiro Sugihara, Javad Shahidi, Toshihiko Doi	162
17	[Comparison of Response to Chemotherapy between Ovarian and Extraovarian Metastasis of Gastric Cancer]. 2017 ·PubMed ·(unknown), Shoko Nakamura, Yusuke Sasaki, Naoki Takahashi, Satoru Iwasa, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi, Narikazu Boku	1
18	Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients 2016 ·Cancer Science ·Satoru Iwasa, Yasuhide Yamada, Yuji Heike, Hirokazu Shoji, Yoshitaka Honma, Nobukazu Komatsu, Satoko Matsueda, Akira Yamada, (unknown), Rin Yamaguchi, Natsuki Tanaka, Akihiko Kawahara, Masayoshi Kage, Shigeki Shichijo, Tetsuro Sasada, Kyogo Itoh	10
19	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients 2016 ·Cancer Immunology Research ·Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike, Tetsuya Hamaguchi	54
20	Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. 2014 ·PubMed ·Hitomi Sumiyoshi Okuma, Satoru Iwasa, Hirokazu Shoji, Atsuo Takashima, Natsuko Okita, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact